Profusa's 10-K Reveals $0 Revenue, $(35.82M) Net Loss Amid Widening Operating Deficit
PFSA sits 62% above its 52-week low of $0.41 on light trading volume (0.1× avg).
Summary
Profusa reported zero revenue and a significant net loss of $(35.82) million in its latest 10-K filing, a substantial increase from the $(9.23) million loss in the prior year. The company also posted an operating loss of $(27.71) million, driven by operating expenses. This dire financial performance, particularly the complete lack of revenue for a company with a very low market capitalization, signals severe financial distress and raises significant going concern risks. This disclosure follows a recent 8-K where Profusa secured new debt and announced a non-binding letter of intent for an acquisition, indicating ongoing efforts to address its precarious financial position. Traders will be closely monitoring any further financing activities or updates on the proposed acquisition as the company continues to burn capital without generating sales.
At the time of this announcement, PFSA was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $901.3K. The 52-week trading range was $0.41 to $975.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.